SEC Filings

AVEXIS, INC. filed this Form 8-K on 01/30/2018
Entire Document


Item 8.01.             Other Events.


On January 30, 2018, AveXis, Inc. (the “Registrant”) issued a press release to announce that the Registrant will initiate screening for the remaining patients in the Registrant’s pivotal trial of AVXS-101 for spinal muscular atrophy Type 1 as per the trial protocol, following review of safety data and early signals of efficacy from the first three patients dosed in the trial and with agreement from the U.S. Food and Drug Administration.  A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01.             Financial Statements and Exhibits.


(d) Exhibits







Exhibit Description



Press Release, dated January 30, 2018, titled “AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 in SMA Type 1 Following Review of Preliminary Data from First Three Patients.”



© AveXis, Inc. All Rights Reserved.